QNCX 8-K: SEC filing

IRulya Therapeutics Inc.

Filed with the SEC on Nov 13, 2026 · accession 0001193125-26-460775

QNCX filed a 8-K (current report) with the SEC on Nov 13, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

IRulya Therapeutics Inc. announced its financial results for the quarter ended September 30, 2026, and provided recent business highlights via a press release furnished as Exhibit 99.1 to the 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantIRulya Therapeutics Inc.

Chief financial officerJohn Militello

✦ Ask GOAX AI about this filing — what it means for QNCX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for QNCX?

Click here

Frequently asked questions

What did QNCX file with the SEC on Nov 13, 2026?

QNCX filed a 8-K (SEC filing). IRulya Therapeutics Inc. announced its financial results for the quarter ended September 30, 2026, and provided recent business highlights via a press release furnished as Exhibit 99.1 to the 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other QNCX SEC filings

Get alerts when QNCX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

QNCX overview QNCX analysis QNCX news Latest SEC filings